Risk stratification for radioactive iodine refractoriness using molecular alterations in distant metastatic differentiated thyroid cancer
- 1 January 2024
- journal article
- research article
- Published by Chinese Journal of Cancer Research in Chinese Journal of Cancer Research
- Vol. 36 (1) , 25-35
Abstract
Patients with radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) are often diagnosed with delay and constrained to limited treatment options. The correlation between RAI refractoriness and the underlying genetic characteristics has not been extensively studied. Adult patients with distant metastatic DTC were enrolled and assigned to undergo next-generation sequencing of a customized 26-gene panel (ThyroLead). Patients were classified into RAIR-DTC or non-RAIR groups to determine the differences in clinicopathological and molecular characteristics. Molecular risk stratification (MRS) was constructed based on the association between molecular alterations identified and RAI refractoriness, and the results were classified as high, intermediate or low MRS. A total of 220 patients with distant metastases were included, 63.2% of whom were identified as RAIR-DTC. Genetic alterations were identified in 90% of all the patients, with BRAF (59.7% vs. 17.3%), TERT promoter (43.9% vs. 7.4%), and TP53 mutations (11.5% vs. 3.7%) being more prevalent in the RAIR-DTC group than in the non-RAIR group, except for RET fusions (15.8% vs. 39.5%), which had the opposite pattern. BRAF and TERT promoter are independent predictors of RAIR-DTC, accounting for 67.6% of patients with RAIR-DTC. MRS was strongly associated with RAI refractoriness (P<0.001), with an odds ratio (OR) of high to low MRS of 7.52 [95% confidence interval (95% CI), 3.96−14.28; P<0.001] and an OR of intermediate to low MRS of 3.20 (95% CI, 1.01−10.14; P=0.041). Molecular alterations were associated with RAI refractoriness, with BRAF and TERT promoter mutations being the predominant contributors, followed by TP53 and DICER1 mutations. MRS might serve as a valuable tool for both prognosticating clinical outcomes and directing precision-based therapeutic interventions.Keywords
This publication has 34 references indexed in Scilit:
- BRAFV600E Mutation Associated With Non–Radioiodine-Avid Status in Distant Metastatic Papillary Thyroid CarcinomaClinical Nuclear Medicine, 2014
- Exome sequencing of pleuropulmonary blastoma reveals frequent biallelic loss of TP53 and two hits in DICER1 resulting in retention of 5p-derived miRNA hairpin loop sequencesOncogene, 2014
- Cell Cycle Deregulation andTP53andRASMutations Are Major Events in Poorly Differentiated and Undifferentiated Thyroid CarcinomasThe Journal of Clinical Endocrinology & Metabolism, 2014
- Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles forBRAF, PIK3CA, andAKT1Cancer Research, 2009
- Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosisCancer, 2007
- Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptakeClinical Endocrinology, 2007
- The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I− targeting to the membraneEndocrine-Related Cancer, 2006
- BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid CancerThe Journal of Clinical Endocrinology & Metabolism, 2005
- Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.Journal of Clinical Investigation, 1993
- High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.Journal of Clinical Investigation, 1993